Finkelstein Thompson LLP is investigating potential claims on behalf of
shareholders of Cigna Corp. (“Cigna” or the “Company”) (NYSE:CI),
concerning the Company’s proposed acquisition by Anthem Inc. Under the
terms of the proposal, Cigna shareholders will receive $188.00 for each
share of Cigna common stock they own. At least one analyst has set a
high target price of $190.00 for Cigna shares. The entire transaction is
valued at approximately $54 billion.
The investigation is focused on whether Cigna’s Board of Directors
breached its fiduciary duty in failing to maximize consideration to
shareholders, the potential unfairness of the consideration to
shareholders, the process by which the Board of Directors considered the
transaction, and potential conflicts of interest among Cigna’s Board of
Directors’ members.
If you are interested in discussing your rights as a Cigna shareholder,
or have information relating to this investigation, please contact
Finkelstein Thompson’s Washington, DC offices at (877) 337-1050 or (202)
337-8000, or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering
outstanding representation to institutional and individual clients in
financial litigation, and has been appointed as lead or co-counsel in
dozens of shareholder class actions. Indeed, the firm has served in
leadership roles in cases that have recovered over $1 billion for
investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our website
at www.finkelsteinthompson.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150727005894/en/
Copyright Business Wire 2015